Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Liebman who wrote (392)	10/11/1999 3:35:00 PM
From: Elmer Flugum	Respond to of 3044

The DNA Detective boston.com "Lander is also an enthusiastic businessman. "Lots of businesses have tried to recruit Eric. Every venture capitalist [has tried] to recruit him for something," says Mark Levin, chief executive of Millennium Pharmaceuticals Inc. of Cambridge, which counts Lander as a founder. In 1997 Millennium agreed, with two other companies, to fund research at the Whitehead genome center in return for an early look at the results. Under Whitehead ethics rules, the deal forced Lander to divest the stock he had received as a Millennium founder, though he is still on the board of directors. Lander will not discuss what he earned on his 749,591 shares. But if he sold them in the two months after the deal was announced, they would have brought between $9.9 million and $13 million. (At one point last month, that same stake would have been worth $56 million.)"